We scour the net for great ideas, so you don't have to
Claim this username to collect earnings from this post, and the portfolio!
Long time watcher, first time poster...
I'm very surprised at the lack of mentions here about WINT, and am honestly wondering why so many are overlooking this potential golden ticket, especially at a time when smaller, heavily shorted bio floats (especially ones with a Covid link) are taking off with the slightest piece of news.
Here's the quick DD breakdown:
One final interesting nugget worth noting here, there's speculation that they will either merge or be bought out by a larger company before end of year. This speculation comes from something that was said during the recent Ladenburg Thalmann Healthcare Conference - Craig Fraser alluded to something "transactional" happening by the end of this year (7:07 mark here).
WINT closed at $1.83 on Friday, that's well over 400% off its one-year high of $10.06. It's badly beaten down, heavily shorted, and primed to run hard once they start releasing news. My price target is $10 by end of year, and $6-7 by end of August (KL4 release). A lot of people either don't know about this stock or are downplaying the importance of their Istaroxime candidate. Their buyout price would be higher than $10 based on their assets and pipeline alone IMO.
As always, do your own DD. This is not financial advice.
Position: 15K shares @ $1.87 and continuing to add as much as I can below $2.